ADAM17 and neoplasm: Based on this experimental evidence, going beyond the natural role in the wound healing response and in the resolution of inflammation, ADAM17 represents a potential source of deregulation in the tumour environment and its therapeutic targeting, when over activated in the tumour environment, either alone or in combination with other immune-modulating therapies, merits investigation.